Redeye will not make any immediate adjustments following the lowered guidance for 2022 from Remedy. Our research update published in April expected relatively slow revenue growth and a significantly lower EBIT compared to 2021. The lowered guidance was therefore expected and has mostly a technical explanation where some development fees will be postponed to 2023, due to optimized cost-control in the development process for the Tencent collaboration codenamed Vanguard.